archive-ie.com » IE » N » NCPE.IE

Total: 381

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • NCPE Corifollitropin alfa (Elvonva®) Assessment | National Centre for Pharmacoeconomics
    HTA Guidelines Process Flowchart Submission Templates Pharmacoeconomic Evaluations Drugs Vaccines Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Corifollitropin alfa Elonva In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Cost effectiveness of Corifollitropin alfa Elonva Rapid Review Commenced Completed Outcome September 2010 22 10 2010 Full Pharmacoeconomic Evaluation not Recommended Terms Conditions Sitemap National

    Original URL path: http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/ (2015-10-30)
    Open archived version from archive


  • NCPE Dienogest (Visanne®) Assessment | National Centre for Pharmacoeconomics
    Guidelines Process Flowchart Submission Templates Pharmacoeconomic Evaluations Drugs Vaccines Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Dienogest Visanne In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Dienogest Visanne for the Treatment of Endometriosi s Rapid Review Commenced Completed Outcome 17 09 2010 04 10 2010 Full Pharmacoeconomic Evaluation Recommended Terms Conditions Sitemap National

    Original URL path: http://www.ncpe.ie/drugs/dienogest-visanne/ (2015-10-30)
    Open archived version from archive

  • NCPE Certolizumab pegol (Cimzia®) Assessment | National Centre for Pharmacoeconomics
    Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Certolizumab pegol Cimzia In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Cost effectiveness of certolizumab pegol Cimzia for the treatment of moderate to severe rheumatoid arthritis Pharmacoeconomic Evaluation Commenced Completed Outcome 13 03 2010 02 09 2010 Reimbursement not Recommended The review group did not consider certolizumab cost effective at

    Original URL path: http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/ (2015-10-30)
    Open archived version from archive

  • NCPE Denosumab (Prolia®) Assessment | National Centre for Pharmacoeconomics
    Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Denosumab Prolia In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive The Cost effectiveness of Denosumab Prolia for the Prevention of Osteoporotic Fractures in Postmenopausal Women Pharmacoeconomic Evaluation Commenced Completed Outcome 27 05 2010 July 2010 Reimbursement Recommended We consider denosumab a cost effective therapy for the prevention of osteoporotic fractures in

    Original URL path: http://www.ncpe.ie/drugs/denosumab-prolia/ (2015-10-30)
    Open archived version from archive

  • NCPE Oral Oxycodone/naloxone (Targin®) Assessment | National Centre for Pharmacoeconomics
    Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Cost effectiveness of oral oxycodone naloxone prolonged release tablet Targin for severe pain which can be adequately managed only with opioid analgesics Pharmacoeconomic Evaluation Commenced Completed Outcome 05 05 2010 12 07 2010 Reimbursement not recommended 19 10 2010 Reimbursement recommended following price revision 13 07 2010 We do not recommend reimbursement of oxycodone naloxone Targin under the

    Original URL path: http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/ (2015-10-30)
    Open archived version from archive

  • NCPE Ofatumumab (Arzerra®) Assessment | National Centre for Pharmacoeconomics
    Pharmacoeconomic Evaluations Drugs Vaccines Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Ofatumumab Arzerra Refractory CLL In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab Rapid Review Commenced Completed Outcome June 2010 22 06 2010 Full Pharmacoeconomic Evaluation

    Original URL path: http://www.ncpe.ie/drugs/ofatumumab-arzerra/ (2015-10-30)
    Open archived version from archive

  • NCPE Golimumab (Simponi®) Assessment | National Centre for Pharmacoeconomics
    Pharmacoeconomic Research ICORN Education Golimumab Simponi In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Cost effectiveness of golimumab Simponi in the treatment of moderate to severe rheumatoid arthritis Pharmacoeconomic Evaluation Commenced Completed Outcome 20 11 2009 11 05 2010 Reimbursement recommended following price review June 2010 The review group did not consider golimumab cost effective at the submitted price in May 2010 Following a

    Original URL path: http://www.ncpe.ie/drugs/golimumab-simponi/ (2015-10-30)
    Open archived version from archive

  • NCPE Colesevelam (Cholestagel®)Assessment | National Centre for Pharmacoeconomics
    HTA Guidelines Process Flowchart Submission Templates Pharmacoeconomic Evaluations Drugs Vaccines Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Colesevelam Cholestagel In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Cost effectiveness of Colesevelam Cholestagel Rapid Review Commenced Completed Outcome 19 10 2010 22 10 2010 Full Pharmacoeconomic Evaluation not Recommended Terms Conditions Sitemap National Centre

    Original URL path: http://www.ncpe.ie/drugs/colesevelam-cholestagel/ (2015-10-30)
    Open archived version from archive